#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
The Neurogenetics Program at Boston Children's provides an innovative approach to genetic disorders of the nervous system with a unique combination of specialized clinical care and dedicated basic science and translational research.
Boston Children's neurogenetics team of physicians, nurses, and genetic counselors provide specialty clinics tailored to the individual needs of the unique patients we serve. Our researchers work diligently to study areas of neurogenetics that will directly contribute to our understanding of these diseases and help us continually improve the clinical care we are able to provide.
The physicians who are involved with the clinics within the Neurogenetics Program all devote their time to clinical and/or translational research.
CDKL5 Clinic (Heather Olson, MD)
The CDKL5 Center of Excellence at Boston Children’s brings together a multispecialty team dedicated to the care and evaluation of children with CDKL5 disorder, a genetic epilepsy syndrome and neurodevelopmental disorder. We collaborate closely with the International Foundation for CDKL5 Research (IFCR).
Mitochondrial Program (Irina Anselm, MD)
Within the Mitochondrial Program we offer an experimental medication, dichloroacetate (DCA), to patients whose mitochondrial disease has caused lactic acidosis, a condition in which there is too much lactate in the blood and spinal fluid. Children’s is one of only a few institutions in the United States where the use of DCA is approved.
The Engle Laboratory (Elizabeth Engle, MD)
The Engle lab is dedicated to study of genetic eye movement disorders which can cause both visual impairment and cosmetic differences. Through this research, the lab has identified and characterized a variety of different eye movement disorders and discovered the genes that cause them. The lab combines clinical, genetic, and molecular biological approaches to the study of these disorders.
The Sahin Laboratory (Mustafa Sahin, MD, PhD)
The Sahin lab is dedicated to understanding the neurological complications, such as seizures, autism, and intellectual disability, which are found in Tuberous Sclerosis (TSC), a genetic condition. Currently, while many children with TSC develop these neurologic complications, the cause is not fully understood. The Sahin lab also focuses on spinal muscular atrophy (SMA) which is a neurogenetic disorder caused by a dysfunctional SMN protein. Dr. Sahin is focusing on the role of SMN protein in the working of the nervous system to gain a better understanding of this disease.
Pediatric Neuromuscular Clinical Research (PNCR) Network (Basil Darras, MD)
This project, funded by the SMA Foundation, seeks to develop the necessary tools and facilities for efficient phase I and II clinical trials in patients with spinal muscular atrophy (SMA). These trials will be aimed at testing candidate drugs and using innovative clinical trial designs to minimize study duration and sample size. These initial studies aim to improve the quality of clinical trials for patients and SMA and maximize the research that is able to be performed for these patients.
Neurofibromatosis Clinical Trials Consortium (Nicole Ullrich, MD)
Boston Children’s Hospital is one of nine sites in the United States that is a part of this consortium. Dr. Ullrich and the rest of the team at BCH work with other physicians and researchers across the country to develop new therapies and treatments for patients with a condition called Neurofibromatosis type 1 (NF1). There are currently three clinical trials taking place at Boston Children’s aimed at treating different symptoms of NF1.
Epilepsy Genetics (Annapurna Poduri, MD)
The Epilepsy Phenome/Genome Project (EPGP) is an international consortium that has come together with the aim of identifying the underlying genetic basis of epilepsy to help shape the future of clinical care for individuals with epilepsy. Dr. Poduri and the Epilepsy Genetics Program also work on a variety of other projects aimed at gene discovery for various types of childhood epilepsy, including a project for Ohtahara syndrome.
Phelan-McDermid Syndrome (PMS)
Our Phelan McDermid Syndrome (PMS) clinic at Boston Children's Hospital combines the expertise of physicians who specialize in treating the various complications associated with SHANK3 mutations and deletions. Mustafa Sahin, MD, PhD, leads our program and is supported by a team of pediatric specialists in Epilepsy, Genetics, Nephrology, and Ophthalmology as well as our Autism Spectrum Center. Additionally, our clinic is participating in a multi-center NIH funded study aimed at comprehensively characterizing the natural history of Phelan-McDermid Syndrome (Developmental Synaptopathies Consortium).
PTEN hamartoma tumor syndrome (PHTS)
Our Multi-Disciplinary PTEN hamartoma tumor syndrome (PHTS) clinic at Boston Children's Hospital includes expert physicians who specialize in treating children with the various complications associated with PTEN related syndromes. Our program is led by child neurologist Mustafa Sahin, MD, PhD, and includes Children's pediatric specialists in Dermatology, Endocrinology, Gastroenterology, Genetics, and Oncology. Each member of our team has special expertise in treating children with PTEN mutations and is dedicated to providing coordinated and centralized cross-disciplinary care. With the hopes of further clarifying clinical care guidelines for treating individuals with PTEN related syndromes the BCH PHTS clinic is participating in a multi-center study aimed at comprehensively characterizing the natural history of PTEN Hamartoma Tumor Syndrome and will also be launching a treatment trial in 2017 (Developmental Synaptopathies Consortium).
Rett Syndrome Program
The Rett Syndrome Research Program at Boston Children’s Hospital is committed to advancing our understanding of Rett syndrome and MECP2-related disorders by running clinical trials and research studies. We are also developing innovative biomarkers that can be used to assess severity and treatment effectiveness in current and future clinical trials. In our Rett Clinic, we are dedicated to helping children and adults develop to their full potential by providing specialized medical care as well as behavioral and rehabilitative therapies. Our aim is to work with families to choose the best combination of therapies and medication to manage symptoms and to promote an environment ideal for learning and development
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”